Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases

Hirotoshi Hasegawa, Masahiko Watanabe, Hideo Baba, Kentaro Yoshinare, Makio Mukai, Tetsuro Kubota, Masaki Kitajima

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We report on two patients with T3N1 rectal cancer treated with a combination of irinotecan, 5-fluorouracil and leucovorin as neoadjuvant chemotherapy. On days 1, 8 and 15 of this 4-week cycle, leucovorin (250mg/m2) was administered in a 2-hour intravenous infusion, followed by 5-fluorouracil (500mg/ m2) in a 10-min intravenous bolus, and then irinotecan (80mg/m2) in a 90-min intravenous infusion. During the chemotherapy, no grade 3-4 texicities were observed. Two weeks after the completion of 2 cycles of this regimen, both patients underwent surgery without postoperative complications. The responses were one pathological and one macroscopic complete response. Both patients with T3 tumors were down-staged to pT0 and pT2, respectively. As for the N stage, both patients were down-staged to pN0. The combination of irinotecan/5-fluorouracil/ leucovorin appears to be feasible and effective, and to have a potential as an optimal neoadjuvant therapy in patients with advanced rectal cancer.

Original languageEnglish
Pages (from-to)891-893
Number of pages3
JournalHepato-Gastroenterology
Volume49
Issue number46
Publication statusPublished - 2002

Fingerprint

irinotecan
Leucovorin
Rectal Neoplasms
Fluorouracil
Drug Therapy
Intravenous Infusions
Neoadjuvant Therapy

Keywords

  • 5-Fluorouracil
  • Irinotecan
  • Leucovorin
  • Neoadjuvant chemotherapy
  • Rectal cancer

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hasegawa, H., Watanabe, M., Baba, H., Yoshinare, K., Mukai, M., Kubota, T., & Kitajima, M. (2002). Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases. Hepato-Gastroenterology, 49(46), 891-893.

Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases. / Hasegawa, Hirotoshi; Watanabe, Masahiko; Baba, Hideo; Yoshinare, Kentaro; Mukai, Makio; Kubota, Tetsuro; Kitajima, Masaki.

In: Hepato-Gastroenterology, Vol. 49, No. 46, 2002, p. 891-893.

Research output: Contribution to journalArticle

Hasegawa, H, Watanabe, M, Baba, H, Yoshinare, K, Mukai, M, Kubota, T & Kitajima, M 2002, 'Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases', Hepato-Gastroenterology, vol. 49, no. 46, pp. 891-893.
Hasegawa, Hirotoshi ; Watanabe, Masahiko ; Baba, Hideo ; Yoshinare, Kentaro ; Mukai, Makio ; Kubota, Tetsuro ; Kitajima, Masaki. / Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases. In: Hepato-Gastroenterology. 2002 ; Vol. 49, No. 46. pp. 891-893.
@article{99984824e28c46c0a636eb0afb4f65c8,
title = "Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases",
abstract = "We report on two patients with T3N1 rectal cancer treated with a combination of irinotecan, 5-fluorouracil and leucovorin as neoadjuvant chemotherapy. On days 1, 8 and 15 of this 4-week cycle, leucovorin (250mg/m2) was administered in a 2-hour intravenous infusion, followed by 5-fluorouracil (500mg/ m2) in a 10-min intravenous bolus, and then irinotecan (80mg/m2) in a 90-min intravenous infusion. During the chemotherapy, no grade 3-4 texicities were observed. Two weeks after the completion of 2 cycles of this regimen, both patients underwent surgery without postoperative complications. The responses were one pathological and one macroscopic complete response. Both patients with T3 tumors were down-staged to pT0 and pT2, respectively. As for the N stage, both patients were down-staged to pN0. The combination of irinotecan/5-fluorouracil/ leucovorin appears to be feasible and effective, and to have a potential as an optimal neoadjuvant therapy in patients with advanced rectal cancer.",
keywords = "5-Fluorouracil, Irinotecan, Leucovorin, Neoadjuvant chemotherapy, Rectal cancer",
author = "Hirotoshi Hasegawa and Masahiko Watanabe and Hideo Baba and Kentaro Yoshinare and Makio Mukai and Tetsuro Kubota and Masaki Kitajima",
year = "2002",
language = "English",
volume = "49",
pages = "891--893",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "46",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases

AU - Hasegawa, Hirotoshi

AU - Watanabe, Masahiko

AU - Baba, Hideo

AU - Yoshinare, Kentaro

AU - Mukai, Makio

AU - Kubota, Tetsuro

AU - Kitajima, Masaki

PY - 2002

Y1 - 2002

N2 - We report on two patients with T3N1 rectal cancer treated with a combination of irinotecan, 5-fluorouracil and leucovorin as neoadjuvant chemotherapy. On days 1, 8 and 15 of this 4-week cycle, leucovorin (250mg/m2) was administered in a 2-hour intravenous infusion, followed by 5-fluorouracil (500mg/ m2) in a 10-min intravenous bolus, and then irinotecan (80mg/m2) in a 90-min intravenous infusion. During the chemotherapy, no grade 3-4 texicities were observed. Two weeks after the completion of 2 cycles of this regimen, both patients underwent surgery without postoperative complications. The responses were one pathological and one macroscopic complete response. Both patients with T3 tumors were down-staged to pT0 and pT2, respectively. As for the N stage, both patients were down-staged to pN0. The combination of irinotecan/5-fluorouracil/ leucovorin appears to be feasible and effective, and to have a potential as an optimal neoadjuvant therapy in patients with advanced rectal cancer.

AB - We report on two patients with T3N1 rectal cancer treated with a combination of irinotecan, 5-fluorouracil and leucovorin as neoadjuvant chemotherapy. On days 1, 8 and 15 of this 4-week cycle, leucovorin (250mg/m2) was administered in a 2-hour intravenous infusion, followed by 5-fluorouracil (500mg/ m2) in a 10-min intravenous bolus, and then irinotecan (80mg/m2) in a 90-min intravenous infusion. During the chemotherapy, no grade 3-4 texicities were observed. Two weeks after the completion of 2 cycles of this regimen, both patients underwent surgery without postoperative complications. The responses were one pathological and one macroscopic complete response. Both patients with T3 tumors were down-staged to pT0 and pT2, respectively. As for the N stage, both patients were down-staged to pN0. The combination of irinotecan/5-fluorouracil/ leucovorin appears to be feasible and effective, and to have a potential as an optimal neoadjuvant therapy in patients with advanced rectal cancer.

KW - 5-Fluorouracil

KW - Irinotecan

KW - Leucovorin

KW - Neoadjuvant chemotherapy

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=0036021306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036021306&partnerID=8YFLogxK

M3 - Article

C2 - 12143234

AN - SCOPUS:0036021306

VL - 49

SP - 891

EP - 893

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 46

ER -